COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis

BACKGROUND: In the aftermath of Covid-19, some patients develop a fibrotic lung disease, i.e., post-COVID-19 lung disease (PCLD), for which we currently lack insights into pathogenesis, disease models, or treatment options. METHODS: Using an AI-guided approach, we analyzed > 1000 human lung trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Saptarshi, Castillo, Vanessa, Espinoza, Celia R., Tindle, Courtney, Fonseca, Ayden G., Dan, Jennifer M., Katkar, Gajanan D., Das, Soumita, Sahoo, Debashis, Ghosh, Pradipta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297827/
https://www.ncbi.nlm.nih.gov/pubmed/35870428
http://dx.doi.org/10.1016/j.ebiom.2022.104185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297827/
https://www.ncbi.nlm.nih.gov/pubmed/35870428
http://dx.doi.org/10.1016/j.ebiom.2022.104185

Ejemplares similares